Developing a Framework for the Health Technology Assessment of Histology-independent Precision Oncology Therapies-Reference-Cited by-同舟云学术

Developing a Framework for the Health Technology Assessment of Histology-independent Precision Oncology Therapies

Published:2021-05-24 Issue:5 Volume:19 Page:625-634
ISSN:1175-5652
Container-title:Applied Health Economics and Health Policy
language:en
Short-container-title:Appl Health Econ Health Policy

Author:

Gaultney Jennifer G.^ORCID,Bouvy Jacoline C.,Chapman Richard H.,Upton Alexander J.,Kowal Stacey,Bokemeyer Carsten,Solà-Morales Oriol,Wolf Jürgen,Briggs Andrew H.

Funder

Bayer Corporation

Publisher

Springer Science and Business Media LLC

Subject

Health Policy,Economics and Econometrics,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s40258-021-00654-4.pdf

Reference36 articles.

1. Guo Y, Cao R, Zhang X, Huang L, Sun L, Zhao J, et al. Recent progress in rare oncogenic drivers and targeted therapy for non-small cell lung cancer. Onco Targets Ther. 2019;12:10343.

2. Torres-Ayuso P, Brognard J. Combing the cancer genome for novel kinase drivers and new therapeutic targets. Cancers. 2019;11(12):1972.

3. Hyman DM, Taylor BS, Baselga J. Implementing genome-driven oncology. Cell. 2017;168(4):584–99.

4. Chalmers ZR, Connelly CF, Fabrizio D, Gay L, Ali SM, Ennis R, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017;9(1):34.

5. Suh JH, Johnson A, Albacker L, Wang K, Chmielecki J, Frampton G, et al. Comprehensive genomic profiling facilitates implementation of the National Comprehensive Cancer Network guidelines for lung cancer biomarker testing and identifies patients who may benefit from enrollment in mechanism-driven clinical trials. Oncologist. 2016;21(6):684.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Healthcare decision-making for tumour-agnostic therapies in Europe: lessons learned;Drug Discovery Today;2024-07

2. Evolving assessment pathways for precision oncology medicines to improve patient access: a tumor-agnostic lens;The Oncologist;2024-04-17

3. Toward Best Practices for Economic Evaluations of Tumor-Agnostic Therapies: A Review of Current Barriers and Solutions;Value in Health;2023-11

4. Challenges and Solutions for the Benefit Assessment of Tumor-Agnostic Therapies in Germany;Value in Health;2023-06